--- title: "Avalo Therapeutics (AVTX) news: offering" url: "https://aibio.space/companies/avalo-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "AVTX offering news: Avalo Therapeutics sets up $75,000,000 at-the-market program with TD Cowen. Avalo Therapeutics, Inc. (NASDAQ: AVTX), United States." --- AVTX Avalo Therapeutics, Inc. NASDAQ · United States # Avalo Therapeutics (AVTX) news AVTX offering news Mergers · 2026-04-28 ## [Avalo Therapeutics agrees to pay $2.25 million for option on $15 million AlmataBio milestone](https://aibio.space/news/avalo-therapeutics-agrees-pay-2-25-million-option-15-million-almatabio/) Avalo can pay $5.125 million in cash or stock within 90 days instead of $15 million owed when a Phase 3 trial doses its first patient. If it does not, the milestone amount becomes $12.75 million. ## Latest Avalo Therapeutics news 1. 2025-06-05 Financings [Avalo Therapeutics sets up $75,000,000 at-the-market program with TD Cowen](https://aibio.space/news/avalo-therapeutics-sets-up-75-000-000-market-program-td-cowen/) Avalo ended an earlier $50.0 million sales agreement with Oppenheimer. Its stock last sold at $3.72 on May 29, 2025. ## Avalo Therapeutics at a glance - **Ticker**: AVTX - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $400.3 million ### Related companies - [Harrow](https://aibio.space/companies/harrow/) NASDAQ: HROW - [Rezolute](https://aibio.space/companies/rezolute/) NASDAQ: RZLT - [Damora Therapeutics](https://aibio.space/companies/damora-therapeutics/) NASDAQ: DMRA - [Protara Therapeutics](https://aibio.space/companies/protara-therapeutics/) NASDAQ: TARA - [Tenaya Therapeutics](https://aibio.space/companies/tenaya-therapeutics/) NASDAQ: TNYA - [Amneal Pharmaceuticals](https://aibio.space/companies/amneal-pharmaceuticals/) NASDAQ: AMRX - [Protagonist Therapeutics](https://aibio.space/companies/protagonist-therapeutics/) NASDAQ: PTGX - [ZyVersa Therapeutics](https://aibio.space/companies/zyversa-therapeutics/) OTC: ZVSA ### Also on NASDAQ - [Modular Medical](https://aibio.space/companies/modular-medical/) MODD - [ABVC BioPharma](https://aibio.space/companies/abvc-biopharma/) ABVC - [Sionna Therapeutics](https://aibio.space/companies/sionna-therapeutics/) SION - [SL Science Holding](https://aibio.space/companies/sl-science/) SLBT - [Ultragenyx Pharmaceutical](https://aibio.space/companies/ultragenyx-pharmaceutical/) RARE - [NeuroPace](https://aibio.space/companies/neuropace/) NPCE ## What Avalo Therapeutics does Avalo Therapeutics is a clinical-stage biotechnology company developing IL-1β-based treatments for immune-mediated inflammatory diseases. Its lead product candidate, abdakibart (AVTX-009), is an anti-IL-1β monoclonal antibody in the Phase 2 LOTUS trial in hidradenitis suppurativa (HS), a chronic inflammatory skin disease. The randomized, double-blind, placebo-controlled trial evaluates abdakibart in approximately 250 adults with moderate to severe HS, and the company expected to report topline data in the second quarter of 2026. The company plans to prepare for pivotal trials after the readout. Abdakibart is subject to a worldwide exclusive license from Eli Lilly and Company, and the company is responsible for its development and commercialization, with milestone and royalty obligations to Lilly. Several legacy programs, including quisovalimab (AVTX-002), are not being pursued clinically, and the company is exploring strategic alternatives for them. | Product or program | What it is | Stage | |---|---|---| | Abdakibart (AVTX-009) | Anti-IL-1β monoclonal antibody for hidradenitis suppurativa | Phase 2 (LOTUS trial) | | Quisovalimab (AVTX-002) | Fully human monoclonal antibody directed against LIGHT | legacy program; not being clinically developed | | AVTX-913 | Nucleotide prodrug for the treatment of a mitochondrial disorder | preclinical | Summarised from the company's [10-K filed Mar 23, 2026](https://www.sec.gov/Archives/edgar/data/1534120/000153412026000011/avtx-20251231.htm). ## Avalo Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Net income (loss) | [-$78.3 million](https://www.sec.gov/Archives/edgar/data/1534120/000153412026000011/) | [-$35.1 million](https://www.sec.gov/Archives/edgar/data/1534120/000153412026000011/) | | Cash from operations | [-$51.5 million](https://www.sec.gov/Archives/edgar/data/1534120/000153412026000011/) | [-$49.1 million](https://www.sec.gov/Archives/edgar/data/1534120/000153412026000011/) | | Cash and equivalents | [$15.9 million](https://www.sec.gov/Archives/edgar/data/1534120/000153412026000049/) | [$134.5 million](https://www.sec.gov/Archives/edgar/data/1534120/000153412026000011/) | | Short-term investments | [$82.5 million](https://www.sec.gov/Archives/edgar/data/1534120/000153412026000049/) | [$0](https://www.sec.gov/Archives/edgar/data/1534120/000153412026000011/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $85.4 million, plus short-term investments of $314.9 million, $400.3 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Avalo Therapeutics Has Avalo Therapeutics raised money recently? Our latest story on this, dated Jun 5, 2025: "Avalo Therapeutics sets up $75,000,000 at-the-market program with TD Cowen". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/avalo-therapeutics-sets-up-75-000-000-market-program-td-cowen/). What is the ticker symbol of Avalo Therapeutics? Avalo Therapeutics, Inc. trades under the ticker AVTX on NASDAQ. Where is Avalo Therapeutics listed? Avalo Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:C6K0. What is the SEC CIK of Avalo Therapeutics? The SEC Central Index Key (CIK) for Avalo Therapeutics, Inc. is 1534120. Its filings are on SEC EDGAR. How many shares does Avalo Therapeutics have outstanding? 53,629,989 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-06. Which country or territory is Avalo Therapeutics listed under? Our directory records Avalo Therapeutics, Inc. under United States. What does Avalo Therapeutics do? Our directory classifies Avalo Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Avalo Therapeutics? The ISIN recorded for Avalo Therapeutics, Inc. is US05338F3064. Does aibio.space cover Avalo Therapeutics? aibio.space lists Avalo Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Avalo Therapeutics incorporated? SEC records list its state or country of incorporation as DE. What does Avalo Therapeutics develop? Avalo Therapeutics is a clinical-stage biotechnology company developing IL-1β-based treatments for immune-mediated inflammatory diseases. Its lead product candidate, abdakibart (AVTX-009), is an anti-IL-1β monoclonal antibody in the Phase 2 LOTUS trial in hidradenitis suppurativa (HS), a chronic inflammatory skin disease. What is Abdakibart (AVTX-009) from Avalo Therapeutics? Abdakibart (AVTX-009): Anti-IL-1β monoclonal antibody for hidradenitis suppurativa Stage: Phase 2 (LOTUS trial). What is Quisovalimab (AVTX-002) from Avalo Therapeutics? Quisovalimab (AVTX-002): Fully human monoclonal antibody directed against LIGHT Stage: legacy program; not being clinically developed. Is Avalo Therapeutics profitable? Avalo Therapeutics, Inc. reported a net loss of $78.3 million for the fiscal year ended Dec 31, 2025, and used $51.5 million of cash in operations, per its annual report to the SEC. How much cash does Avalo Therapeutics have? $400.3 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. ## Investor discussion: Avalo Therapeutics Members talk about Avalo Therapeutics (AVTX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Avalo Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-06-12 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,3.03,5.02,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1534120/000153412026000040/avtx-20260611.htm) 2. 2026-05-05 Financings Filed a final prospectus for a securities offering. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1534120/000110465926055665/tm2613419-1_424b5.htm) 3. 2026-04-28 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1534120/000153412026000026/ex-991almatamilestonerelea.htm) 4. 2026-01-08 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1534120/000110465926002118/tm261721-1_s3.htm) 5. 2025-10-01 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1534120/000153412025000009/ex-991cboappointmentinduce.htm) 6. 2025-06-05 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1534120/000162828025029637/avalo424b5atmprospectussup.htm) 7. 2025-01-02 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1534120/000162828025000005/ex-991csoappointment.htm) 8. 2024-11-12 Financings Reported a financing. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1534120/000162828024046852/ex-991fullwarrantexercise.htm) 9. 2024-11-07 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1534120/000162828024045965/avtx-20240930.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:AVTX on TradingView](https://www.tradingview.com/symbols/NASDAQ-AVTX/). ## SEC filings and registration - **SEC name**: Avalo Therapeutics, Inc. - **CIK**: 1534120 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: AVTX (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 1500 LIBERTY RIDGE DRIVE, WAYNE, PA, 19087 - **Phone**: 410-522-8707 - **Shares outstanding**: 53,629,989 as of 2026-08-03 (10-Q filed 2026-08-06) - **Former names**: Cerecor Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/1534120/000153412026000049/avtx-20260630.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1534120/000153412026000048/avtx-20260806.htm) filed 2026-08-06 - [S-3](https://www.sec.gov/Archives/edgar/data/1534120/000110465926084609/tm2620167-1_s3.htm) filed 2026-07-17 - [8-K](https://www.sec.gov/Archives/edgar/data/1534120/000153412026000044/avtx-20260623.htm) filed 2026-06-23 - [8-K](https://www.sec.gov/Archives/edgar/data/1534120/000153412026000042/avtx-20260616.htm) filed 2026-06-16 - [8-K](https://www.sec.gov/Archives/edgar/data/1534120/000153412026000040/avtx-20260611.htm) filed 2026-06-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1534120/000153412026000036/avtx-20260602.htm) filed 2026-06-08 - [10-Q](https://www.sec.gov/Archives/edgar/data/1534120/000153412026000033/avtx-20260331.htm) filed 2026-05-13 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001534120), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Avalo Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker AVTX, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Avalo Therapeutics, Inc. - **Ticker**: AVTX - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US05338F3064 - **Other listed symbols**: GETTEX:C6K0 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-AVTX/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/avalo-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Avalo Therapeutics (AVTX) news: offering", 2026-10-31, https://aibio.space/companies/avalo-therapeutics/